15 August 2013
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Notice of results and shareholder update
Allergy Therapeutics plc (AIM: "AGY" or the "Company"), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will announce its Preliminary Results for the year ended 30 June 2013 on Monday 16 September 2013.
The Company also announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will release its interim results for the period ended 30 June 2013 on the 15 August 2013. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.
Balance Sheet as at 31 March 2013
|
£ '000 |
Total Non-Current Assets |
13,837 |
Total Current Assets |
18,198 |
Total Current Liabilities |
(6,913) |
Total Non-Current Liabilities |
(5,493) |
Total Equity |
19,630 |
Consolidated Income Statement for the 6 months ended 31 March 2013
|
£'000 |
Revenue |
26,760 |
Profit after tax for the period |
4,564 |
Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2012.
-Ends-
For further information
Allergy Therapeutics |
+44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer Ian Postlethwaite Finance Director |
|
|
|
Nomura Code Securities |
+44 (0) 207 776 1200 |
Juliet Thompson/ Clare Terlouw |
|
